[Use of synthetic inhibitors in coagulation physiological tests with peptide substrates].
D000409:Alanine / Q000031:analogs & derivatives / Q000494:pharmacology; D000578:Amidines / Q000494:pharmacology*; D001550:Benzamidines / Q000494:pharmacology*; D003911:Dextrans / Q000494:pharmacology; D004789:Enzyme Activation / Q000187:drug effects; D005170:Factor X / Q000032:analysis* / Q000378:metabolism; D005175:Factor XII Deficiency / Q000097:blood; D015951:Factor Xa; D006467:Hemophilia A / Q000097:blood; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007610:Kallikreins / Q000037:antagonists & inhibitors*; D009842:Oligopeptides; D010644:Phenprocoumon / Q000627:therapeutic use; D010714:Phosphatidylethanolamines / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011480:Protease Inhibitors / Q000494:pharmacology*; D013917:Thrombin / Q000037:antagonists & inhibitors*; D014757:Viper Venoms / Q000494:pharmacology
D000578:Amidines; D001550:Benzamidines; D003911:Dextrans; D009842:Oligopeptides; D010714:Phosphatidylethanolamines; D010880:Piperidines; D011480:Protease Inhibitors; D014757:Viper Venoms; C015608:benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide; D005170:Factor X; D006493:Heparin; D007610:Kallikreins; D013917:Thrombin; D015951:Factor Xa; D000409:Alanine; D010644:Phenprocoumon
Einsatz von synthetischen Inhibitoren bei gerinnungsphysiologischen Tests mit Peptidsubstraten.